Many prescription Type 2 diabetes drugs—including
Diabetes drugs linked to pancreatic cancer and pancreatitis.
Pancreatic cancer and thyroid cancer are extremely serious conditions. If you or a loved one took Bydureon, Byetta, Janumet, Januvia, Tradjenta, or Victoza and developed pancreatic or thyroid cancer, we want to help. Contact us today.
Other drugs in this category that have been linked to pancreatic and thyroid cancer include:
- Bydureon
- Tradjenta
- Victoza
Diabetes drugs are used my millions of people across the planet. They help diabetics regulate their blood sugar levels. Diabetes drugs are necessary to help keep diabetics alive. However, some diabetes drugs may be doing as much harm as good for diabetics. Pancreatic cancer and pancreatitis can be very deadly medical conditions. Pancreatic cancer is one of the most deadly forms of cancer because most victims don’t know they have it until symptoms are severe. At this time, our drug injury lawyers are investigating the link between diabetes drugs and pancreatic problems.
About pancreatic cancer and pancreatitis lawsuits.
If you took Byetta®, Janumet®, Januvia®, or Onglyza® and later developed pancreatitis or pancreatic cancer, you may be entitled to a settlement from the drug manufacturer. After developing pancreatic cancer or pancreatitis, there can be major medical bills. A settlement from the drug manufacturer could help your family with the mounting medical bills.
Help for those that lost a loved one that used diabetes drugs.
If your family lost a loved one from pancreatic cancer or pancreatitis after using diabetes drugs, you may also be entitled to a settlement from the drug manufacturer. After a family members loses their battle with pancreatic cancer and pancreatitis, the family may be left with mountains of medical bills. There could be help for families left behind after a diabetes drug user passes away.
Byetta® has been linked to pancreatitis and pancreatic cancer.
Byetta is a diabetes drug that may increase the possibility of pancreatitis and pancreatic cancer. The FDA began issuing healthcare provider alerts in 2007 that Byetta may present an increased risk of pancreatitis in Byetta users. In 2011, University of California researchers found that Byetta users had three times the risk of pancreatic cancer.
How Janumet® may cause pancreatitis and pancreatic cancer.
Janumet helps the body control blood sugar levels. Janumet affects the GLP-1 metabolic pathway, which is in the pancreas. GLP-1 drugs can increase chronic inflammation, encourage cell proliferation, reduce normal cell degradation, change cell responses, inhibit the immune systems ability to fight cancer, reduce normal cell death, which make cancer more likely.
Januvia® may also cause pancreatic cancer and pancreatitis.
Januvia is also known as sitagliptin. Januvia is a medicine designed to treat Type 2 Diabetes symptoms. Januvia works by controlling blood sugar levels. Januvia is a dipeptidyl peptidase-4 inhibitor (DPP-IV) that was released in 2006 by Merck & Co. that has effectively been used to treat diabetes. Researchers found Januvia users were 2.7-times more likely to develop pancreatic cancer.
Januvia is also known as sitagliptin. Januvia is a medicine designed to treat Type 2 Diabetes symptoms. Januvia works by controlling blood sugar levels. Januvia is a dipeptidyl peptidase-4 inhibitor (DPP-IV) that was released in 2006 by Merck & Co. that has effectively been used to treat diabetes. Researchers found Januvia users were 2.7-times more likely to develop pancreatic cancer.
For a free legal consultation about Januvia injuries, just fill out the online contact form or call toll-free 1-866-232-5777.
Symptoms of Januvia Related Pancreatic Cancer
- Unexplained Weight Loss
- Jaundice
- Fatty Stools
- Pale-colored Stools
- Abdominal Pain
- Back Pain
- Bloating
- Nausea
- Diarrhea
Byetta® and Bydureon® are a registered trademarks of Amylin Pharmaceuticals, Inc. Januvia® and Janumet® are registered trademarks of Merck & Co., Inc. Tradjenta® is a registered trademark of Boehringer Ingelheim International GmbH. Victoza® is a registered trademark of Novo Nordisk A/S.
This law firm is not associated with, sponsored by, or affiliated with the U.S. Food and Drug Administration, Amylin Pharmaceuticals, Inc., Merck & Co., Inc, Boehringer Ingelheim International GmbH, or Novo Nordisk A/S.